跳至主要内容
临床试验/EUCTR2015-004526-33-IE
EUCTR2015-004526-33-IE进行中(未招募)1 期

A Randomised Controlled Trial of Early Targeted Patent Ductus Arteriosus Treatment Using a Risk Based Severity Score - PDA RCT

Royal College of Surgeons in Ireland0 个研究点目标入组 60 人开始时间: 2015年12月3日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • All infants less than 29 weeks admitted to the NICU with a PDA identified on echocardiography between 36 and 48 hours of life will be eligible for inclusion. A comprehensive assessment of PDA significance will be performed using echocardiography to derive a PDA risk score based on this following formula: Infants with a risk score = 5.0 are deemed to be at high risk of developing CLD/Death and will be randomised to either arm
  • (Gestation in weeks × -1.304) + (PDA diameter in mm × 0.781) + (Left ventricular output in ml/kg/min × 0.008) + (maximum PDA velocity in m/s × -1.065) + (LV a` wave in cm/s × -0.470) + 41, where 41 is the constant of the formula.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • The following infants will be excluded:
  • lack of consent or study investigators
  • lethal congenital abnormality or obvious syndrome
  • pulmonary hypoplasia
  • active bleeding
  • known or suspected NEC
  • platelet count < 100/mm2
  • creatinine > 100 µmol/L; neutropenia
  • oliguria < 1ml/kg/hour
  • congenital heart disease other than a PDA or a patent foramen ovale
  • grade 3 or higher IVH

研究者

相似试验